A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Study sponsor: Tonix Pharmaceuticals, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-09-28Actual
Enrollment · participants375Actual
Source updated2025-02-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.